日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Quemliclustat联合化疗(加或不加zimberelimab)治疗转移性胰腺腺癌:一项随机1期试验

Wainberg, Zev A; Manji, Gulam A; Bahary, Nathan; Ulahannan, Susanna V; Pant, Shubham; Spigel, David R; Uboha, Nataliya V; Oberstein, Paul E; Saeed, Anwaar; Beagle, Brandon; Kim, Ji Yun; Wang, Ning; Weeder, Ben; Shitole, Shravani; Mrouj, Karim; Scott, Jennifer R; Ensign, Lisa G; DiRenzo, Daniel M; Walters, Matthew J; Wu, Wilson; Kaplan, Angelo; Cho, Soonweng; Kabbarah, Omar; O'Reilly, Eileen M

Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial

新辅助改良FOLFIRINOX方案联合纳武利尤单抗治疗临界可切除胰腺导管腺癌:一项I期试点试验

Wainberg, Zev A; Link, Jason M; Premji, Alykhan; Zheng, Serena; Srienc, Michael; Hammons, McKensie; Kim, Shineui E; Li, Luyi; Liu, Zeyu; Tsvetkova, Olga; Abt, Evan R; Rosen, Lee; Kim, Stephen; King, Jonathan; Hines, O Joe; Girgis, Mark; Sadeghi, Saeed; Olevsky, Olga; Wong, Deborah; Yonemoto, Lisa; Siney, Ann Marie; Kelly, Kim; Kivork, Christine; Tseng, Chi-Hong; Radu, Caius G; Dawson, David W; Donahue, Timothy R

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma

一项针对未经治疗的转移性胰腺腺癌患者的吉西他滨/白蛋白紫杉醇联合纳武利尤单抗/伊匹木单抗或羟氯喹/伊匹木单抗的1期临床试验的临床和转化结果

O'Reilly, Eileen M; Cabanski, Christopher R; Lyman, Jaclyn P; Wainberg, Zev A; Fisher, George A; Wolff, Robert A; Ko, Andrew H; O'Hara, Mark H; Spencer, Christine N; Yu, Jia Xin; Da Silva, Diane M; Padrón, Lacey J; Arnott, Jamie; Fairchild, Justin; Moore, Jonni S; Peng, Brandon; Hoos, William A; O'Donnell-Tormey, Jill; Boffo, Silvia; Dugan, Ute; Kimmelman, Alec C; Amaravadi, Ravi K; Vonderheide, Robert H

Domvanalimab and zimberelimab in advanced gastric, gastroesophageal junction or esophageal cancer: a phase 2 trial

Domvanalimab 和 zimberelimab 治疗晚期胃癌、胃食管交界处癌或食管癌:一项 II 期试验

Janjigian, Yelena Y; Oh, Do-Youn; Pelster, Meredith; Wainberg, Zev A; Prusty, Subhransu; Nelson, Sandahl; DuPage, Amy; Thompson, Amy; Koralek, Daniel O; Sison, Edward Allan R; Rha, Sun Young

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study

乐伐替尼联合帕博利珠单抗和化疗对比单纯化疗治疗晚期转移性胃食管腺癌:III期随机LEAP-015研究

Shitara, Kohei; Lorenzen, Sylvie; Li, Jin; Bai, Yuxian; Fernández, Manuel González; Aguilar, Mynor; Shoji, Hirokazu; Reyes-Cosmelli, Felipe; Peña, Yovany Rodriguez; Corrales, Luis; Wyrwicz, Lucjan; Eyzaguirre, Daniel Acosta; Pan, Yueyin; Ryu, Min-Hee; Cohen, Deirdre J; Wainberg, Zev A; Ku, Geoffrey; Tabernero, Josep; Van Cutsem, Eric; Qin, Shu-Kui; Oh, Do-Youn; Xu, Jianming; Liang, Li Wen; Bordia, Sonal; Bhagia, Pooja; Rha, Sun Young

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish

DKN-01联合替雷利珠单抗和化疗作为晚期胃癌或胃食管交界处腺癌的一线治疗:DisTinGuish

Klempner, Samuel J; Sonbol, Mohamad Bassam; Wainberg, Zev A; Uronis, Hope Elizabeth; Chiu, Vi K; Scott, Aaron James; Iqbal, Syma; Tejani, Mohamedtaki Abdulaziz; Chung, Vincent; Stilian, Melissa C; Thoma, Mathis; Zhang, Ying; Kagey, Michael H; Baum, Jason; Sirard, Cynthia A; Altura, Rachel A; Ajani, Jaffer A

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies

一项针对对标准疗法无效的不可切除的局部晚期或转移性实体瘤患者的sacituzumab tirumotecan 1/2期研究结果

Ouyang, Quchang; Rodon, Jordi; Liang, Yan; Wu, Xinhong; Li, Qun; Song, Lihua; Yan, Min; Tong, Zhongsheng; Liu, YunPeng; Wainberg, Zev A; Wang, Ying; Geng, Cuizhi; Ulahannan, Susanna V; Yu, Guohua; Sharma, Manish R; Wang, Xiang; Wang, Judy S; Spira, Alexander; Zhao, Weihong; Sanborn, Rachel E; Cheng, Ying; Wang, Xian; Liu, Gesha; Li, Yaling; Ge, Junyou; Chartash, Elliot; Akala, Omobolaji O; Yin, Yongmei

Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial

FORTITUDE-101 III期试验预筛选期间晚期胃癌中FGFR2b蛋白过表达的患病率

Rha, Sun Young; Zhang, Yanqiao; Elme, Anneli; Pazo Cid, Roberto; Alacacioglu, Ahmet; Ziogas, Dimitrios C; Shitara, Kohei; Ranceva, Anastasija; Nemecek, Radim; Santoro, Armando; Calderon, Carlos Alberto; Korphaisarn, Krittiya; Davis, Tracy; Zahlten-Kuemeli, Anita; Conn, Christopher; Tan, Mengyao; Honeycutt, Hayden; Wainberg, Zev A

Genomic Landscape of Late-Stage Gastric Cancer: Analysis From KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Studies

晚期胃癌的基因组图谱:来自 KEYNOTE-059、KEYNOTE-061 和 KEYNOTE-062 研究的分析

Janjigian, Yelena Y; Cecchini, Michael; Shitara, Kohei; Enzinger, Peter C; Wainberg, Zev A; Chau, Ian; Satoh, Taroh; Lee, Jeeyun; Nebozhyn, Michael; Loboda, Andrey; Kobie, Julie; Vajdi, Amir; Shih, Chie-Schin; Cristescu, Razvan; Cao, Z Alexander

Erratum: Prevalence of FGFR2b Protein Overexpression in Advanced Gastric Cancers During Prescreening for the Phase III FORTITUDE-101 Trial

更正:在 III 期 FORTITUDE-101 试验的预筛选期间,晚期胃癌中 FGFR2b 蛋白过表达的患病率

Rha, Sun Young; Zhang, Yanqiao; Elme, Anneli; Cid, Roberto Pazo; Alacacioglu, Ahmet; Ziogas, Dimitrios C; Shitara, Kohei; Ranceva, Anastasija; Nemecek, Radim; Santoro, Armando; Calderon, Carlos Alberto; Korphaisarn, Krittiya; Davis, Tracy; Zahlten-Kuemeli, Anita; Conn, Christopher; Tan, Mengyao; Honeycutt, Hayden; Wainberg, Zev A